东阳光长江药业(01558)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01558 东阳光长江药业

已收盘 11-19 16:08:17

9.630

+0.120

+1.26%

最高9.690	最低9.470	成交量129.74万
今开9.510	昨收9.510	日振幅2.31%
总市值84.74亿	流通市值62.98亿	总股本8.80亿
成交额1,245万	换手率0.20%	流通股本6.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01558","market":"HK","secType":"STK","nameCN":"东阳光长江药业","latestPrice":9.63,"timestamp":1732003697012,"preClose":9.51,"halted":0,"volume":1297400,"delay":0,"floatShares":654000000,"shares":879967700,"eps":2.4326353,"marketStatus":"已收盘","marketStatusCode":5,"change":0.12,"latestTime":"11-19 16:08:17","open":9.51,"high":9.69,"low":9.47,"amount":12449424,"amplitude":0.023134,"askPrice":9.64,"askSize":1200,"bidPrice":9.63,"bidSize":1800,"shortable":3,"etf":0,"ttmEps":2.0089082150417132,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"listingDate":1451318400000,"adjPreClose":9.51,"openAndCloseTimeList":[[1731979800000,1731988800000],[1731992400000,1732003200000]],"volumeRatio":0.430441,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01558","defaultTab":"news","newsList":[{"id":"2483534564","title":"东阳光长江药业11月15日遭主力抛售333万元 环比增加974.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483534564","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483534564?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:17","pubTimestamp":1731658623,"startTime":"0","endTime":"0","summary":"11月15日, 东阳光长江药业股价涨2.24%，报收9.60元，成交金额2519万元，换手率0.41%，振幅2.88%，量比1.03。东阳光长江药业今日主力资金净流出333万元，上一交易日主力净流出31万元，今日环比增加974.19%。该股近5个交易日上涨6.33%，主力资金累计净流出564万元；近20日主力资金累计净流出81万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161750a23a5826&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161750a23a5826&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01558","BK1515"],"gpt_icon":0},{"id":"2483029494","title":"大摩：Sunshine 管道净现值得到支持 看涨东阳光长江药业(01558)至13.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483029494","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483029494?lang=zh_cn&edition=full","pubTime":"2024-11-13 15:55","pubTimestamp":1731484532,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华尔街大行摩根士丹利近日发布研报称，Sunshine (母公司)将FGF21/GLP-1的中国以外权利授权给Apollo Therapeutics，交易价值大约9.38亿美元。这为Sunshine管道的净现值预期提供了强劲支持。大摩在这份研报中予以东阳光长江药业 “增持”评级，目标股价则予以13.8港元。大摩表示，Sunshine将从Apollo Therapeutics获得高达1200万美元的预付款，以及多达9.26亿美元的开发里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1989772840.SGD","LU1668664300.SGD","BK1191","BK4504","LU1720051108.HKD","BK4581","LU0971096721.USD","BK4516","LU2357305700.SGD","LU0267386448.USD","LU1548497426.USD","LU0106261372.USD","BK4127","LU1162221912.USD","LU1989772923.USD","BK1515","BK4534","LU0225283273.USD","LU1074936037.SGD","LU0006306889.USD","01558","LU1720051017.SGD","LU0320765646.SGD","BK4585","LU1363072403.SGD","BK4588","LU0314104364.USD","IE00BZ1G4Q59.USD","LU0106831901.USD","LU0098860793.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2483902210","title":"超9亿美元BD交易展现全球商业化潜力，东阳光长江药业(01558)估值新增量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2483902210","media":"智通财经","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483902210?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:03","pubTimestamp":1731463439,"startTime":"0","endTime":"0","summary":"11月12日晚间，东阳光长江药业发布的一则公告引发业界和市场广泛关注。东阳光长江药业宣布与Apollo Therapeutics就公司自主研发的FGF21/GLP-1双特异性融合蛋白HEC88473签署了一项总价达9.38亿美元的高里程碑独家许可协议。此次合作刷新了国内GLP-1/FGF21双功能分子的BD交易金额新纪录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2483921980","title":"东阳光长江药业现涨超6% 与Apollo就HEC88473项目海外权益达成授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2483921980","media":"新浪港股","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483921980?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:38","pubTimestamp":1731461929,"startTime":"0","endTime":"0","summary":"东阳光长江药业（01558）早盘上涨6.01%，现报9.52港元，成交额532.87万港元。\n　　东阳光长江药业公布，与Apollo达成授权许可协议，向Apollo授予公司自主研发的HEC88473项目在大中华区以外地区的独家开发和商业化权益，并保留大中华区的开发和商业化权益。根据协议，公司有望在协议的有效期内收取最高9.38亿美元的款项，包括1200万美元的首付款和最高9.26亿美元的开发、监管及商业里程碑付款。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-13/doc-incvwrzr1433305.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-13/doc-incvwrzr1433305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2483092842","title":"港股异动 | 东阳光长江药业(01558)涨超6% 与Apollo就HEC88473项目海外权益达成授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2483092842","media":"智通财经","labels":["Company Corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483092842?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:33","pubTimestamp":1731461584,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东阳光长江药业(01558)涨超6%，截至发稿，涨6.01%，报9.52港元，成交额532.87万港元。消息面上，东阳光长江药业公布，与Apollo达成授权许可协议，向Apollo授予公司自主研发的HEC88473项目在大中华区以外地区的独家开发和商业化权益，并保留大中华区的开发和商业化权益。根据协议，公司有望在协议的有效期内收取最高9.38亿美元的款项，包括1200万美元的首付款和最高9.26亿美元的开发、监管及商业里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2483924270","title":"东阳光长江药业盘中异动 早盘大幅上涨5.01%报9.430港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483924270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483924270?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:30","pubTimestamp":1731461439,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘09时30分，东阳光长江药业股票出现异动，股价快速拉升5.01%。截至发稿，该股报9.430港元/股，成交量16.52万股，换手率0.03%，振幅4.23%。资金方面，该股资金流入65.3206万港元，流出23.231万港元。东阳光长江药业股票所在的药品行业中，整体跌幅为0.12%。其相关个股中，开拓药业-B、东阳光长江药业、四环医药涨幅较大，振幅较大的相关个股有开拓药业-B、东阳光长江药业、康龙化成，振幅分别为7.03%、4.23%、2.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093039abbb7e3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093039abbb7e3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2483451037","title":"东阳光长江药业(01558.HK)向Apollo授出HEC88473项目许可权","url":"https://stock-news.laohu8.com/highlight/detail?id=2483451037","media":"阿斯达克财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483451037?lang=zh_cn&edition=full","pubTime":"2024-11-13 02:29","pubTimestamp":1731436140,"startTime":"0","endTime":"0","summary":"东阳光长江药业(01558.HK) 公布，与Apollo达成授权许可协议，向Apollo授予公司自主研发的HEC88473项目在大中华区以外地区的独家开发和商业化权益，并保留大中华区的开发和商业化权益。根据协议，公司有望在协议的有效期内收取最高9.38亿美元的款项，包括1,200万美元的首付款和最高9.26亿美元的开发、监管及商业里程碑付款。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-12 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190627171508424_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190627171508424_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396099/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2482707257","title":"东阳光长江药业(01558)：东阳光药与 Apollo 公司就开发及商业化HEC88473 项目达成授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2482707257","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482707257?lang=zh_cn&edition=full","pubTime":"2024-11-12 21:47","pubTimestamp":1731419220,"startTime":"0","endTime":"0","summary":"东阳光长江药业及要约人广东东阳光药业股份有限公司联合公布，2024 年 11 月 12 日，广东东阳光药业股份有限公司与 Apollo Therapeutics Group Limited宣布就东阳光药自主研发的 HEC88473 项目达成授权许可协议，东阳光药授予 Apollo 关于 HEC88473 在大中华区以外地区的独家开发和商业化权益，并保留大中华区的开发和商业化权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-12/doc-incvvkhh8806190.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-12/doc-incvvkhh8806190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK0003","BK1191","BK0028","600673","BK0188","BK0012","01558","BK0070","BK0265"],"gpt_icon":0},{"id":"2482709471","title":"9.38亿美元！东阳光新药海外授权取得重要突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2482709471","media":"中金在线","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482709471?lang=zh_cn&edition=full","pubTime":"2024-11-12 20:59","pubTimestamp":1731416352,"startTime":"0","endTime":"0","summary":"根据协议条款，东阳光药将保留APL-18881在中国的开发、生产和商业化权利，并授予Apollo Therapeutics该药物在全球其他地区开发、生产和商业化所有当前和未来适应症的权利。目前，APL-18881正在中国开展一项针对2型糖尿病患者的双盲、安慰剂和阳性药物对照II期临床试验，预计将于2025年上半年获得主要结果。东阳光药与Apollo Therapeutics在APL-18881项目上的合作标志着东阳光药在新型生物药方面的首次国际合作伙伴关系，进一步强调了东阳光药对全球化的承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112210139a2308cb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112210139a2308cb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","01558","600673"],"gpt_icon":0},{"id":"2478733581","title":"东阳光长江药业10月28日主力资金流入83万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2478733581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478733581?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:15","pubTimestamp":1730103314,"startTime":"0","endTime":"0","summary":"10月28日，东阳光长江药业股价收平报9.16元，成交金额748万元，换手率0.13%，振幅1.97%，量比0.64。东阳光长江药业今日主力资金净流入83万元，连续3日净流入，上一交易日主力净流入45万元，今日环比增加84.44%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为63.64%，平均涨幅为2.98%。该股近5个交易日上涨1.78%，主力资金累计净流入457万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出2339万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028161524a1f14503&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028161524a1f14503&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","01558"],"gpt_icon":0},{"id":"2476492337","title":"南向资金10月17日净买入东阳光长江药业105.10万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2476492337","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476492337?lang=zh_cn&edition=full","pubTime":"2024-10-18 09:30","pubTimestamp":1729215014,"startTime":"0","endTime":"0","summary":"10月17日, 南向资金增持东阳光长江药业105.10万股，连续5日增持。截止当日收盘，港股通共持有东阳光长江药业9494.96万股，占流通股14.51%。港股通增持金额前五个股分别为建设银行、中芯国际、工商银行、中国银行、协鑫科技。东阳光长江药业近5个交易日下跌6.17%，港股通累计增持557.70万股；近20个交易日上涨1.09%，港股通累计增持1651.82万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410180932059f4b99e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410180932059f4b99e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2475623165","title":"南向资金10月15日净买入东阳光长江药业64.86万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2475623165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475623165?lang=zh_cn&edition=full","pubTime":"2024-10-16 09:30","pubTimestamp":1729042214,"startTime":"0","endTime":"0","summary":"10月15日, 南向资金增持东阳光长江药业64.86万股，连续3日增持。截止当日收盘，港股通共持有东阳光长江药业9357.22万股，占流通股14.30%。东阳光长江药业近5个交易日下跌15.83%，港股通累计增持593.58万股；近20个交易日下跌5.65%，港股通累计增持1510.54万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410160932209f45fd31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410160932209f45fd31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01558","BK1515"],"gpt_icon":0},{"id":"2475826358","title":"东阳光长江药业修订持续关联交易年度上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2475826358","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475826358?lang=zh_cn&edition=full","pubTime":"2024-10-14 17:03","pubTimestamp":1728896582,"startTime":"0","endTime":"0","summary":"财中社10月14日电东阳光长江药业（01558）发布公告，计划修订与深圳东阳光实业的持续关联交易年度上限，预计将显著提高相关金额。公告中指出，租赁及其他服务框架协议的年度上限将从1300万元上调至4536万元，增加了约249%。委托加工框架协议的年度上限也将提升，从1.08亿元增至1.37亿元，增幅约25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202410143205476193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","01558","BK1191"],"gpt_icon":0},{"id":"2474956957","title":"东阳光长江药业10月10日主力资金流入19万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2474956957","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474956957?lang=zh_cn&edition=full","pubTime":"2024-10-10 16:16","pubTimestamp":1728548192,"startTime":"0","endTime":"0","summary":"10月10日, 东阳光长江药业股价跌1.35%，报收8.80元，成交金额3106万元，换手率0.53%，振幅4.37%，量比0.84。东阳光长江药业今日主力资金净流入19万元，连续3日净流入，上一交易日主力净流入63万元，今日环比减少69.84%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为54.55%，平均涨幅为2.42%。该股近5个交易日下跌3.30%，主力资金累计净流入62万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3597万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010161742959cde80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010161742959cde80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","01558"],"gpt_icon":0},{"id":"2473465851","title":"东阳光长江药业盘中异动 早盘快速跳水5.04%报9.420港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2473465851","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473465851?lang=zh_cn&edition=full","pubTime":"2024-10-08 10:11","pubTimestamp":1728353511,"startTime":"0","endTime":"0","summary":"2024年10月08日早盘10时11分，东阳光长江药业股票出现异动，股价急速下挫5.04%。截至发稿，该股报9.420港元/股，成交量245.52万股，换手率0.38%，振幅9.88%。东阳光长江药业股票所在的药品行业中，整体跌幅为0.86%。其相关个股中，三爱健康集团、华控康泰、长江生命科技涨幅较大，振幅较大的相关个股有三爱健康集团、艾美疫苗、华控康泰，振幅分别为57.14%、42.54%、32.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008101151ab6842c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008101151ab6842c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","01558"],"gpt_icon":0},{"id":"2473128929","title":"东阳光长江药业盘中异动 急速拉升5.04%报9.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2473128929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473128929?lang=zh_cn&edition=full","pubTime":"2024-10-07 14:19","pubTimestamp":1728281959,"startTime":"0","endTime":"0","summary":"2024年10月07日下午盘14时19分，东阳光长江药业股票出现波动，股价快速上涨5.04%。截至发稿，该股报9.800港元/股，成交量266.28万股，换手率0.41%，振幅5.25%。资金方面，该股资金流入1000.58万港元，流出1285.95万港元。东阳光长江药业股票所在的药品行业中，整体涨幅为0.32%。东阳光长江药业公司简介：宜昌东阳光长江药业股份有限公司是一家主要从事药品生产及销售业务的中国公司。该公司产品包括抗病毒药物、内分泌及代谢药物及心血管药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241007141919a1de9e79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241007141919a1de9e79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01558","BK1191","BK1515"],"gpt_icon":0},{"id":"2472466903","title":"东阳光长江药业10月03日主力资金流出1094万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2472466903","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472466903?lang=zh_cn&edition=full","pubTime":"2024-10-03 16:16","pubTimestamp":1727943419,"startTime":"0","endTime":"0","summary":"10月03日, 东阳光长江药业股价跌4.21%，报收9.10元，成交金额4336万元，换手率0.72%，振幅6.11%，量比1.14。东阳光长江药业今日主力资金净流出1094万元，连续3日净流出，上一交易日主力净流出793万元，今日环比增加37.96%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为50.00%，平均跌幅为1.72%。该股近5个交易日上涨7.44%，主力资金累计净流出2818万元；近20日主力资金累计净流出3957万元，其中净流出天数为14日。该股主力净额占比0.18%，港股市场排名2583/2639。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241003161822958d3885&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241003161822958d3885&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01558","BK1515"],"gpt_icon":0},{"id":"2472755636","title":"东阳光长江药业(01558)下跌5.05%，报9.02元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2472755636","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472755636?lang=zh_cn&edition=full","pubTime":"2024-10-03 10:07","pubTimestamp":1727921246,"startTime":"0","endTime":"0","summary":"10月3日，东阳光长江药业(01558)盘中下跌5.05%，截至10:07，报9.02元/股，成交2215.51万元。宜昌东阳光长江药业股份有限公司是一家专注于抗病毒、内分泌及代谢性疾病、心血管疾病等治疗领域产品的开发、生产与销售的制药企业，公司产品在中国市场占据重要地位，其中产品磷酸奥司他韦颗粒剂是中国市场唯一的生产商。根据标点医药提供的数据，公司在2014年进入抗流感病毒产品市场前四强，而在2013年和2014年，公司磷酸奥司他韦产品的销量在中国区名列前茅。截至2024年中报，东阳光长江药业营业总收入24.55亿元、净利润6.85亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/10/03100743714959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2472639168","title":"东阳光长江药业盘中异动 早盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472639168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472639168?lang=zh_cn&edition=full","pubTime":"2024-10-03 10:07","pubTimestamp":1727921246,"startTime":"0","endTime":"0","summary":"2024年10月03日早盘10时07分，东阳光长江药业股票出现异动，股价急速下挫5.05%。截至发稿，该股报9.020港元/股，成交量237.48万股，换手率0.36%，振幅6.11%。东阳光长江药业股票所在的药品行业中，整体跌幅为0.71%。东阳光长江药业公司简介：宜昌东阳光长江药业股份有限公司是一家主要从事药品生产及销售业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410031007279719e1a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410031007279719e1a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2472477655","title":"港股创新药“迎牛而上”，东阳光长江药业(01558)低估修复标的配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2472477655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472477655?lang=zh_cn&edition=full","pubTime":"2024-10-02 20:33","pubTimestamp":1727872389,"startTime":"0","endTime":"0","summary":"而其中，东阳光长江药业作为板块内同时满足\"港股通优质企业”和“低估价值股”的稀缺可选标的，值得投资者重点关注。从当前公司股价情况来看，今年5月至今，东阳光长江药业的股价已随港股创新药板块波动调整到位，PE估值处在明显历史低位。也就是说，整合后的东阳光药将成为港股创新药板块内一支典型的低估修复标的，存在很大的估值上修空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1189804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1161","BK1574","HSTECH","YANG","BK1191","01558","BK1515","159992"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.hec-changjiang.com","stockEarnings":[{"period":"1week","weight":0.0661},{"period":"1month","weight":0.0869},{"period":"3month","weight":-0.0345},{"period":"6month","weight":-0.082},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.0021}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜昌东阳光长江药业股份有限公司是一家主要从事药品生产及销售业务的中国公司。其业务还包括药品的研发、营销及分销。该公司产品包括抗病毒药物、内分泌及代谢药物及心血管药物。其核心产品组合包括“可威”、“尔同舒”、“欧美宁”、“欣海宁”及 “喜宁”。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052152},{"month":2,"riseRate":0.777778,"avgChangeRate":0.088442},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.0661},{"month":4,"riseRate":0.666667,"avgChangeRate":0.018306},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.018369},{"month":6,"riseRate":0.666667,"avgChangeRate":0.070024},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.05594},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.04223},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.045743},{"month":10,"riseRate":0.444444,"avgChangeRate":0.024617},{"month":11,"riseRate":0.777778,"avgChangeRate":0.137582},{"month":12,"riseRate":0.5,"avgChangeRate":0.005825}],"exchange":"SEHK","name":"东阳光长江药业","nameEN":"HEC CJ PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光长江药业(01558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光长江药业(01558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光长江药业,01558,东阳光长江药业股票,东阳光长江药业股票老虎,东阳光长江药业股票老虎国际,东阳光长江药业行情,东阳光长江药业股票行情,东阳光长江药业股价,东阳光长江药业股市,东阳光长江药业股票价格,东阳光长江药业股票交易,东阳光长江药业股票购买,东阳光长江药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光长江药业(01558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光长江药业(01558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}